Q-omics provides the consensus-scored RAP1BP2 profile across patient tissues and cancer cell-line models. RAP1BP2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RAP1BP2 is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, RAP1BP2 RNA expression shows 4,247 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UCEC, ESCA, and COAD as cancer lineages where RAP1BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP1BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP1BP2 survival associations across molecular data types. RAP1BP2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP1BP2 RNA expression–survival associations across cancer types. High RAP1BP2 expression shows unfavorable associations in UCEC, DLBC, THYM, LUAD, KIRC and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RAP1BP2 RNA expression.
This table summarizes RAP1BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for RAP1BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP1BP2 shows higher tumor expression in ESCA. The ESCA box plot shows higher RAP1BP2 RNA expression in tumor versus normal tissue (log2 FC = +0.105, t-test p = .019).
This table shows molecular features associated with RAP1BP2 in patient tissues and cancer cell lines. In patient samples, RAP1BP2 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
